Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.60 |
| ▸ | DRD3 | P35462 | 7/20 | 0.60 |
| ▸ | DRD1 | P21728 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 6/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR7 | P34969 | 4/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.56 |
| ▸ | DRD5 | P21918 | 3/20 | 0.56 |
| ▸ | HRH1 | P35367 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 3/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711971 | 0.85 | KCNH2 (0.71) | DRD2DRD3DRD1POLBKCNH2 | |
| SCHEMBL19954286 | 0.84 | DRD2 (0.55) | DRD2DRD3DRD1POLBKCNH2 | |
| SCHEMBL30416085 | 0.84 | DRD2 (0.55) | DRD2DRD3DRD1POLBKCNH2 | |
| SCHEMBL26108725 | 0.81 | KCNH2 (0.85) | DRD2DRD3DRD1POLBKCNH2 | |
| SCHEMBL4519313 | 0.81 | KCNH2 (0.85) | DRD2DRD3DRD1POLBKCNH2 | |
| SCHEMBL26107525 | 0.81 | KCNH2 (0.85) | DRD2DRD3DRD1POLBKCNH2 | |
| Hydrochloric Acid SCHEMBL11060044 | 0.80 | POLB (0.64) | DRD2DRD3DRD1POLBKCNH2 | |
| SCHEMBL11070192 | 0.80 | KCNH2 (0.64) | DRD2DRD3DRD1POLBKCNH2 | |
| SCHEMBL1307947 | 0.80 | KCNH2 (0.64) | DRD2DRD3DRD1POLBKCNH2 | |
| SCHEMBL2522222 | 0.80 | POLB (0.64) | DRD2DRD3DRD1POLBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | DRD2 4335/4885DRD3 4705/4885DRD1 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.